Clinical Trials
Page 7 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework
The EMA's Hybrid Trial Framework revolutionizes drug development by integrating real-world evidence, improving outcomes for patients with chronic conditions.
Pediatric Clinical Trials EU: Impact of Revised Pediatric Investigation Plan
This article examines how the revised Pediatric Investigation Plan influences pediatric clinical trials in the EU, focusing on drug XYZ for childhood asthma.
Adagene's Muzastotug Shows 66.7% Response Rate in Triple Combination Therapy for Hepatocellular Carcinoma at AACR 2026
Adagene's muzastotug demonstrates superior efficacy in combination therapy for liver cancer, achieving 66.7% response rate versus 32.5% control in Phase 1b/2 trial.
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study
Sanofi's protein-based Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in first head-to-head phase 4 study presented at ESCMID.
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
AIM ImmunoTech plans Phase 3 trial for Ampligen in pancreatic cancer, backed by positive Phase 2 data and orphan drug designations in US and Europe.
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
AB Science obtains €25M clinical trial insurance for masitinib ALS Phase III study while implementing temporary European trial halt amid regulatory review.
Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
Beamion's zongertinib gains FDA accelerated approval for HER2-mutant NSCLC treatment following breakthrough therapy designation and NEJM publication.
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
TRI-611 molecular glue degrader gains FDA fast track status for ALK-positive NSCLC while Eisai's taletrectinib advances in Europe for ROS1+ lung cancer treatment.
Traws Pharma Advances Tivoxavir Marboxil to Human Influenza Challenge Trial, Reports Positive Ratutrelvir COVID Data
Traws Pharma advances tivoxavir marboxil for once-monthly flu prevention and reports differentiated COVID treatment data for ratutrelvir versus Paxlovid.
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
TME Pharma announces Nature Communications publication of NOX-A12 triple therapy Phase 1/2 GLORIA trial results for brain cancer treatment.
Boehringer Ingelheim and Zai Lab Launch Phase Ib/II Trial for DLL3-Targeting Combination Therapy in Small Cell Lung Cancer
Boehringer Ingelheim partners with Zai Lab to test obrixtamig plus zocilurtatug pelitecan combination in Phase Ib/II trial for SCLC and neuroendocrine carcinomas.
IMVT-1402 and 7 Other Late-Stage Drugs Transform Generalized Myasthenia Gravis Treatment Pipeline in 2026
Eight promising late-stage drugs including IMVT-1402 from Immunovant signal breakthrough era for generalized myasthenia gravis patients with novel mechanisms.